{
  "model": "o1",
  "prompt_version": "v3",
  "prompt_name": "Dual format (rsID + genotype)",
  "timestamp": "2026-01-19T21:20:28.186033",
  "use_supplements": true,
  "use_variant_context": true,
  "per_article_results": [
    {
      "pmcid": "PMC5508045",
      "has_supplement": true,
      "variants": [
        {
          "variant": "rs9923231",
          "variant_context": "Also known as: VKORC1 1639G>A, VKORC1 -1639G>A, VKORC1 rs9923231 reference (C), VKORC1 -1252G>A",
          "generated": "Genotypes GA + AA of rs9923231 are associated with decreased dose of warfarin as compared to genotype GG.",
          "ground_truth": [
            "Genotypes CT + TT are associated with decreased dose of warfarin in people with Atrial Fibrillation, heart valve replacement, Hypertension, Pulmonary, Pulmonary Embolism or Venous Thrombosis as compared to genotype CC."
          ],
          "best_similarity": 0.3939393939393939,
          "best_match_idx": 0,
          "best_match": "Genotypes CT + TT are associated with decreased dose of warfarin in people with Atrial Fibrillation, heart valve replacement, Hypertension, Pulmonary, Pulmonary Embolism or Venous Thrombosis as compared to genotype CC.",
          "all_similarities": [
            0.3939393939393939
          ]
        },
        {
          "variant": "rs1057910",
          "variant_context": "Also known as: CYP2C9*1, CYP2C9 1075A>C",
          "generated": "Genotypes *1/*3 + *3/*3 of CYP2C9 (rs1057910) are associated with decreased stable weekly dose of warfarin as compared to genotype *1/*1.",
          "ground_truth": [
            "Genotypes AC + CC are associated with decreased dose of warfarin in people with Atrial Fibrillation, heart valve replacement, Hypertension, Pulmonary, Pulmonary Embolism and Venous Thrombosis as compared to genotype AA."
          ],
          "best_similarity": 0.3611111111111111,
          "best_match_idx": 0,
          "best_match": "Genotypes AC + CC are associated with decreased dose of warfarin in people with Atrial Fibrillation, heart valve replacement, Hypertension, Pulmonary, Pulmonary Embolism and Venous Thrombosis as compared to genotype AA.",
          "all_similarities": [
            0.3611111111111111
          ]
        },
        {
          "variant": "rs2108622",
          "variant_context": "",
          "generated": "Genotype TT of rs2108622 is associated with increased stable warfarin dose requirements as compared to genotype CC.",
          "ground_truth": [
            "Genotype TT is associated with increased dose of warfarin in people with Atrial Fibrillation, heart valve replacement, Hypertension, Pulmonary, Pulmonary Embolism and Venous Thrombosis as compared to genotype CC."
          ],
          "best_similarity": 0.4482758620689655,
          "best_match_idx": 0,
          "best_match": "Genotype TT is associated with increased dose of warfarin in people with Atrial Fibrillation, heart valve replacement, Hypertension, Pulmonary, Pulmonary Embolism and Venous Thrombosis as compared to genotype CC.",
          "all_similarities": [
            0.4482758620689655
          ]
        },
        {
          "variant": "rs887829",
          "variant_context": "Also known as: UGT1A1 -364C>T, UGT1A1*80",
          "generated": "Genotypes CT + TT of UGT1A1 rs887829 are not associated with stable warfarin dose as compared to genotype CC.",
          "ground_truth": [
            "Allele C is not associated with dose of warfarin in people with Atrial Fibrillation, heart valve replacement, Hypertension, Pulmonary, Pulmonary Embolism and Venous Thrombosis as compared to allele T."
          ],
          "best_similarity": 0.25,
          "best_match_idx": 0,
          "best_match": "Allele C is not associated with dose of warfarin in people with Atrial Fibrillation, heart valve replacement, Hypertension, Pulmonary, Pulmonary Embolism and Venous Thrombosis as compared to allele T.",
          "all_similarities": [
            0.25
          ]
        }
      ],
      "avg_similarity": 0.3633315917798676
    },
    {
      "pmcid": "PMC554812",
      "has_supplement": false,
      "variants": [
        {
          "variant": "HLA-B*58:01",
          "variant_context": "",
          "generated": "HLA-B*58:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol as compared to individuals without HLA-B*58:01.",
          "ground_truth": [
            "HLA-B *58:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol."
          ],
          "best_similarity": 0.6190476190476191,
          "best_match_idx": 0,
          "best_match": "HLA-B *58:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.",
          "all_similarities": [
            0.6190476190476191
          ]
        },
        {
          "variant": "HLA-DRB1*03:01",
          "variant_context": "",
          "generated": "HLA-DRB1*03:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol as compared to noncarriers.",
          "ground_truth": [
            "HLA-DRB1 *03:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol."
          ],
          "best_similarity": 0.65,
          "best_match_idx": 0,
          "best_match": "HLA-DRB1 *03:01 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.",
          "all_similarities": [
            0.65
          ]
        },
        {
          "variant": "HLA-C*03:02",
          "variant_context": "",
          "generated": "\"HLA-C*03:02 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol as compared to the absence of HLA-C*03:02.\"",
          "ground_truth": [
            "HLA-C *03:02 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol."
          ],
          "best_similarity": 0.6190476190476191,
          "best_match_idx": 0,
          "best_match": "HLA-C *03:02 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.",
          "all_similarities": [
            0.6190476190476191
          ]
        },
        {
          "variant": "HLA-A*33:03",
          "variant_context": "",
          "generated": "\"HLA-A*33:03 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol as compared to individuals lacking HLA-A*33:03.\"",
          "ground_truth": [
            "HLA-A *33:03 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol."
          ],
          "best_similarity": 0.6190476190476191,
          "best_match_idx": 0,
          "best_match": "HLA-A *33:03 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol.",
          "all_similarities": [
            0.6190476190476191
          ]
        },
        {
          "variant": "rs1594",
          "variant_context": "",
          "generated": "Carriage of rs1594 is associated with increased risk of severe cutaneous adverse reactions when treated with allopurinol as compared to non-carriers.",
          "ground_truth": [
            "Allele A is associated with severe cutaneous adverse reactions when treated with allopurinol as compared to allele G."
          ],
          "best_similarity": 0.5909090909090909,
          "best_match_idx": 0,
          "best_match": "Allele A is associated with severe cutaneous adverse reactions when treated with allopurinol as compared to allele G.",
          "all_similarities": [
            0.5909090909090909
          ]
        }
      ],
      "avg_similarity": 0.6196103896103896
    }
  ],
  "avg_similarity": 0.5057087016857131,
  "total_variants": 9,
  "articles_with_supplements": 1
}